PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis

Journal of Hepatology

Volumn 63, Issue 1, 2015, Pages 164-173

  Francque, Sven ^a,b   Verrijken, An ^a,b   Caron, Sandrine ^c   Prawitt, Janne ^c   Paumelle, Réjane ^c   Derudas, Bruno ^c   Lefebvre, Philippe ^c   Taskinen, Marja Riitta ^d   Van Hul, Wim ^b   Mertens, Ilse ^a,b   Hubens, Guy ^a   Van Marck, Eric ^a   Michielsen, Peter ^a,b   Van Gaal, Luc ^a,b   Staels, Bart ^c  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIV LILLE   (France)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Follow up study; Metabolic syndrome; Non alcoholic steatohepatitis; Pathophysiology; Peroxisome proliferator activated receptor

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LACTATE DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TISSUE PLASMINOGEN ACTIVATOR; RNA;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; BIOPSY; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOPSY; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HUMANS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PPAR ALPHA; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RNA; YOUNG ADULT;

EID: 84931577111     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.02.019     Document Type: Article

References (38)

1. G. Vernon, A. Baranova, and Z.M. Younossi Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults Aliment Pharmacol Ther 34 2011 274 285
2. E. Vanni, E. Bugianesi, A. Kotronen, S. De Minicis, H. Yki-Jarvinen, and G. Svegliati-Baroni From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 42 2010 320 330
3. A. Lonardo, S. Bellentani, V. Ratziu, and P. Loria Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - Death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 5 2011 279 289
4. R. Pais, I. Moraru, and V. Ratziu Glitazones for human nonalcoholic steatohepatitis Therap Adv Gastroenterol 4 2011 325 334
5. B. Staels, A. Rubenstrunk, B. Noel, G. Rigou, P. Delataille, and L.J. Millatt Hepato-protective effects of the dual PPARalpha/delta agonist GFT505 in rodent models of NAFLD/NASH Hepatology 58 2013 1941 1952
6. A. Tailleux, K. Wouters, and B. Staels Roles of PPARs in NAFLD: Potential therapeutic targets Biochim Biophys Acta 5 2012 809 818
7. P. Lefebvre, G. Chinetti, J.C. Fruchart, and B. Staels Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis J Clin Invest 116 2006 571 580
8. W. Shan, P.S. Palkar, I.A. Murray, E.I. McDevitt, M.J. Kennett, and B.H. Kang Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression Toxicol Sci 105 2008 418 428
9. C. Fievet, and B. Staels Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease Curr Atheroscler Rep 11 2009 281 288
10. E. Ip, G.C. Farrell, G. Robertson, P. Hall, R. Kirsch, and I. Leclercq Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice Hepatology 38 2003 123 132
11. E.R. Kallwitz, A. McLachlan, and S.J. Cotler Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease World J Gastroenterol 14 2008 22 28
12. E. Ip, G. Farrell, P. Hall, G. Robertson, and I. Leclercq Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice Hepatology 39 2004 1286 1296
13. S. Francque, A. Verrijken, I. Mertens, G. Hubens, E. Van Marck, and P. Pelckmans Non-cirrhotic human NAFLD induces portal hypertension in relation to the histological degree of steatosis Eur J Gastroenterol Hepatol 22 2010 1449 1457
14. D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, and O.W. Cummings Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
15. N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, and K. Cusi The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Am J Gastroenterol 107 2012 811 826
16. B. Lefebvre, Y. Benomar, A. Guedin, A. Langlois, N. Hennuyer, and J. Dumont Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans J Clin Invest 120 2010 1454 1468
17. S. Song, R.R. Attia, S. Connaughton, M.I. Niesen, G.C. Ness, and M.B. Elam Peroxisome proliferator activated receptor alpha (PPARalpha) and PPAR gamma coactivator (PGC-1alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements Mol Cell Endocrinol 325 2010 54 63
18. T. Inagaki, P. Dutchak, G. Zhao, X. Ding, L. Gautron, and V. Parameswara Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21 Cell Metab 5 2007 415 425
19. E.M. Brunt Liver biopsy diagnosis of hepatitis: clues to clinically-meaningful reporting Mo Med 107 2010 113 118
20. S.M. Francque, A. Verrijken, I. Mertens, G. Hubens, E. Van Marck, and P. Pelckmans Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients Clin Gastroenterol Hepatol 10 2012 1162 1168
21. K. Promrat, D.E. Kleiner, H.M. Niemeier, E. Jackvony, M. Kearns, and J.R. Wands Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis Hepatology 51 2010 121 129
22. A.J. Sanyal, E.M. Brunt, D.E. Kleiner, K.V. Kowdley, N. Chalasani, and J.E. Lavine Endpoints and clinical trial design for nonalcoholic steatohepatitis Hepatology 54 2011 344 353
23. V. Ratziu, S. Bellentani, H. Cortez-Pinto, C. Day, and G. Marchesini A position statement on NAFLD/NASH based on the EASL 2009 special conference J Hepatol 53 2010 372 384
24. F. Lalloyer, K. Wouters, M. Baron, S. Caron, E. Vallez, and J. Vanhoutte Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice Arterioscler Thromb Vasc Biol 31 2011 1573 1579
25. C.Z. Larter, M.M. Yeh, D.M. Van Rooyen, J. Brooling, K. Ghatora, and G.C. Farrell Peroxisome proliferator-activated receptor-alpha agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis J Gastroenterol Hepatol 27 2012 341 350
26. C. Fernandez-Miranda, M. Perez-Carreras, F. Colina, G. Lopez-Alonso, C. Vargas, and J.A. Solis-Herruzo A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease Dig Liver Dis 40 2008 200 205
27. M. Nakamuta, S. Morizono, Y. Soejima, T. Yoshizumi, S. Aishima, and S. Takasugi Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation Transplantation 80 2005 608 612
28. M. Basaranoglu, O. Acbay, and A. Sonsuz A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis J Hepatol 31 1999 384
29. J. Laurin, K.D. Lindor, J.S. Crippin, A. Gossard, G.J. Gores, and J. Ludwig Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study Hepatology 23 1996 1464 1467
30. B. Cariou, R. Hanf, S. Lambert-Porcheron, Y. Zair, V. Sauvinet, and B. Noel Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects Diabetes Care 36 2013 2923 2930
31. A. Verrijken, S. Francque, I. Mertens, M. Talloen, F. Peiffer, and L. Van Gaal Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients Int J Obes (Lond) 34 2010 899 907
32. T. Kanda, J.D. Brown, G. Orasanu, S. Vogel, F.J. Gonzalez, and J. Sartoretto PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice J Clin Invest 119 2009 110 124
33. A. Rogue, C. Spire, M. Brun, N. Claude, and A. Guillouzo Gene expression changes induced by PPAR gamma agonists in animal and human liver PPAR Res 2010 2010 325183
34. P. Pettinelli, and L.A. Videla Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction J Clin Endocrinol Metab 96 2011 1424 1430
35. E. Lima-Cabello, M.V. Garcia-Mediavilla, M.E. Miquilena-Colina, J. Vargas-Castrillon, T. Lozano-Rodriguez, and M. Fernandez-Bermejo Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C Clin Sci (Lond) 120 2011 239 250
36. G. Musso, R. Gambino, M. Cassader, and G. Pagano A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease Hepatology 52 2010 79 104
37. V. Ratziu, F. Charlotte, C. Bernhardt, P. Giral, M. Halbron, and G. Lenaour Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial Hepatology 51 2010 445 453
38. J.I. Odegaard, R.R. Ricardo-Gonzalez, E.A. Red, D. Vats, C.R. Morel, and M.H. Goforth Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance Cell Metab 7 2008 496 507